Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OHRP

OHR Pharmaceutical (OHRP) Stock Price, News & Analysis

OHR Pharmaceutical logo

About OHR Pharmaceutical Stock (NASDAQ:OHRP)

Key Stats

Today's Range
N/A
50-Day Range
$5.39
$9.07
52-Week Range
N/A
Volume
N/A
Average Volume
180,228 shs
Market Capitalization
$1.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive OHRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OHR Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OHRP Stock News Headlines

Pharmaceutical Stocks
CYCC Cyclacel Pharmaceuticals, Inc.
Warren Buffett Issues Cryptic Warning on U.S. Dollar
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
OHR Pharmaceutical (OHRP) is now in Oversold Territory
See More Headlines

OHRP Stock Analysis - Frequently Asked Questions

OHR Pharmaceutical Inc (NASDAQ:OHRP) announced its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.20) earnings per share for the quarter.

OHR Pharmaceutical's stock reverse split before market open on Monday, February 4th 2019.The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 1st 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that OHR Pharmaceutical investors own include Actinium Pharmaceuticals (ATNM), TherapeuticsMD (TXMD), IVERIC bio (OPHT), Cytori Therapeutics (CYTX), Novavax (NVAX), Immunomedics (IMMU) and Synergy Pharmaceuticals (SGYP).

Company Calendar

Last Earnings
8/14/2018
Today
9/17/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OHRP
CIK
1173281
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.23 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-75.46%
Return on Assets
-71.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.73
Quick Ratio
3.73

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.86 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,829,000
Free Float
N/A
Market Cap
$1.08 million
Optionable
Not Optionable
Beta
0.84
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:OHRP) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners